Current assets cover short-term debt with room to spare. Quick ratio 1.25×. 2024 was 2.56×.
Opening company
COMPANY OVERVIEW
Opening company
Org. no. 985 525 331·Aksjeselskap
Etablering og drift av diagnostisk laboratorium, forskning og konsulenttjenester samt alt som står i forbindelse med dette, publisering av vitenskapelige artikler nasjonalt og internasjonalt, herunder investeringer i andre selskaper og fast eiendom.
Register details are shown now. Website, social and contact listings fill in as they are found.
post@patogen.noBrønnøysundregistrene email
Checking public listings
Company contact from public listings — not a verified direct line to an executive.
Loading annual accounts
Registered group structure from Brønnøysundregistrene. Ownership basis is shown as filed.
Officially registered management, board members and other roles. Each person is looked up by name on 1881 and Gulesider. A number is shown when that listing, Proff or the company website matches this person.
Org. no. 985 525 331·Aksjeselskap
Etablering og drift av diagnostisk laboratorium, forskning og konsulenttjenester samt alt som står i forbindelse med dette, publisering av vitenskapelige artikler nasjonalt og internasjonalt, herunder investeringer i andre selskaper og fast eiendom.
Company-supplied registry link. Official ownership and availability have not been independently verified.
post@patogen.noBrønnøysundregistrene email
Company contact from public listings — not a verified direct line to an executive.
Officially registered management, board members and other roles. Each person is looked up by name on 1881 and Gulesider. A number is shown when that listing, Proff or the company website matches this person.
Current assets cover short-term debt with room to spare. Quick ratio 1.25×. 2024 was 2.56×.
Equity is a large share of total assets. 2024 was 69%.
The operating margin is modest.
Calculated from the annual accounts filed with Brønnøysundregistrene. These bands describe the filed figures. They are not a credit rating. Changes are against the 2024 filing.